| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445648 | European Journal of Cancer | 2012 | 10 Pages |
Abstract
Despite receiving first- and second-line treatment, most patients with advanced melanoma have short survival times and poor prognoses, reinforcing the need for new treatments.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
C. Lebbe, P. Lorigan, P. Ascierto, A. Testori, C. Bédane, M. Middleton, M. van Baardewijk, C. Konto, A. Dueymes, M. Maio,